Jump to main content
Jump to site search

Issue 10, 2017
Previous Article Next Article

Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer

Author affiliations

Abstract

ALK-fusion proteins play a fundamental role in the development of about 5% of non-small cell lung cancers. Herein, we identified the compound 5067-0952 as a potent ALK inhibitor, which inhibited cell growth, induced apoptosis, and suppressed the phosphorylation of ALK, subsequently blocking its downstream signaling pathway.

Graphical abstract: Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer

Back to tab navigation

Publication details

The article was received on 21 Jun 2017, accepted on 24 Aug 2017 and first published on 25 Aug 2017


Article type: Research Article
DOI: 10.1039/C7MD00305F
Citation: Med. Chem. Commun., 2017,8, 1914-1918
  •   Request permissions

    Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer

    L. Luo, Y. Li, Y. Niu, Y. Wang, Q. Wang, X. Fan, J. Xu, L. Liu, E. L. Leung and X. Yao, Med. Chem. Commun., 2017, 8, 1914
    DOI: 10.1039/C7MD00305F

Search articles by author

Spotlight

Advertisements